贵州地区临床分离近平滑念珠菌复合群分布及其生物膜形成相关基因研究

摘要/Abstract

摘要： 目的研究贵州地区近平滑念珠菌复合群临床分布和药敏特点,检测近平滑念珠菌生物膜形成能力及其CDC28基因的表达水平。方法收集贵州地区2所三级甲等医院送检标本中分离出的菌株,利用BACTEC^TM FX仪、Phoenix-100仪对菌种进行鉴定,通过基因测序对近平滑念珠菌复合群各分型菌株进行鉴定;采用ATB FUNGUS 3试剂盒检测菌株体外药物敏感情况;检测血源性近平滑念珠菌生物膜形成能力及利用qRT-PCR技术检测它们的CDC28基因表达水平。结果共分离鉴定出163株近平滑念珠菌复合群,其中近平滑念珠菌I型、II型和III型分别占73.0%、6.1%和20.9%;尿液和血液是分离菌株最多的标本(均为50株);血液途径感染的菌株中,I型、II型和 III型分别占54.0%、10.0%和36.0%;三种基因型菌株对常见抗真菌药物无明显耐药性;17株临床菌株中,16株(94.1%)具有生物膜形成能力,其中2株、4株和10株菌株生物膜形成能力强、一般、弱, CDC28在2株生物膜形成能力强以及3株生物膜形成能力一般的菌株中表达上调。结论分离的近平滑念珠菌复合群以I型感染为主,三种基因型菌株对抗真菌药物无明显耐药性;不同血源性近平滑念珠菌生物膜形成能力不同,CDC28基因与近平滑念珠菌生物膜形成有关。

关键词: 近平滑念珠菌感染, 临床特征, 药物敏感特征, 生物膜形成, 基因表达

Abstract: Objective The distribution of infection and drug susceptibility characteristics of Candida parapsilosis complex strains were studied in Guizhou. Detection of the biofilm formation capacity of strains and the expression level of its CDC28 gene were performed. Methods The BACTEC^TM FX and Phoenix-100 instrument were used to identify the strains isolated in there tertiary first class hospitals in Guizhou from January 2017 to December 2019. The Candida parapsilosis complex group was identified by gene sequencing. ATB FUNGUS 3 kit was used to detect drug susceptibility of strains. The Candida parapsilosis biofilms formation capacitywas detected, and the expression levels of their CDC28 genes were detected using qRT-PCR. Results A total of 163 strains of Candida parapsilosis complex were isolated and identified, of which Candida parapsilosis type I, II and III accounted for 73.0%, 6.1% and 20.9% respectively. Urine and blood specimens got the most isolated strains (both 50 strains). Among the ioslates from infected bloodstream, type I, II and III accounted for 54.0%, 10.0% and 36.0% respectively. Three genotype strains were not significantly resistant to antifungal drugs. Among the 17 clinical strains, 16 (94.1%) had biofilm formation ability, of which 2, 4 and 10 strains had strong, general and weak biofilm formation capacity. CDC28 expressed upregulation in 2 strains with strong and 3 strains with general ability. Conclusion The isolated Candida parapsilosis complex was dominated by type I, and the three genotype strains were not obviously resistant to antifungal drugs. Different Candida parapsilosis showed different biofilm formation capacity, and the CDC28 gene might be associated with biofilm formation.

Key words: Candida parapsilosis infection, clinical characteristics, drug susceptibility characteristics, biofilm formation, gene expression

中图分类号:

R379.4

王顺, 李红, 瞿玉洁, 李婷婷, 金婷婷, 胡方芳, 罗振华. 贵州地区临床分离近平滑念珠菌复合群分布及其生物膜形成相关基因研究[J]. 中国真菌学杂志, 2023, 18(4): 301-309.

WANG Shun, LI Hong, QU Yujie, LI Tingting, JIN Tingting, HU Fangfang, LUO Zhenhua. A study on the distribution and the biofilm formation related genes of Candida parapsilosis complex clinically isolated in Guizhou area[J]. Chinese Journal of Mycology, 2023, 18(4): 301-309.

参考文献

[1] GUO J, ZHANG M, QIAO D, et al. Prevalence and antifungal susceptibility of Candida parapsilosis species complex in eastern China: A 15-year retrospective study by ECIFIG[J]. Front Microbiol, 2021, 12: 644000. DOI: 10.3389/fmicb.2021.644000.
[2] MARCOS-ARIAS C, MATEO E, JURADO-MARTIN I, et al. Utility of two PCR-RFLP-based techniques for identification of Candida parapsilosis complex blood isolates[J]. Mycoses, 2020, 63(5): 461-470.
[3] TAVANTI A, DAVIDSON A D, GOW N A, et al. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III[J]. J Clin Microbiol, 2005, 43(1): 284-292.
[4] CHEN C Y, SHENG W H, HUANG S Y, et al. Clinical characteristics and treatment outcomes of patients with candidaemia due to Candida parapsilosis sensu lato species at a medical centre in Taiwan, 2000-12[J]. J Antimicrob Chemother, 2015, 70(5): 1531-1538.
[5] 吕志华, 冯丽娜, 李艳. 2016至2018年某医院真菌血流感染者流行病学特征及耐药性分析[J]. 中华实验和临床感染病杂志:电子版, 2020, 14(5): 429-432.
[6] PAPPAS P G, LIONAKIS M S, ARENDRUP M C, et al. Invasive candidiasis[J]. Nat Rev Dis Primers, 2018, 4: 18026. DOI: 10.1038/nrdp.2018.26.
[7] ARIKAN-AKDAGLI S, GULMEZ D, DOGAN O, et al. First multicentre report of in vitro resistance rates in candidaemia isolates in Turkey[J]. J Glob Antimicrob Resist, 2019, 18: 230-234. DOI: 10.1016/j.jgar.2019.04.003.
[8] 罗振华, 吴建伟, 付萍, 等. 人工合成家蝇抗真菌肽MAF-1A体外抗真菌效果及扫描电镜观察[J]. 时珍国医国药, 2014, 25(3): 532-536.
[9] 成荣. 抗真菌肽MAF-1A抗近平滑念珠菌作用机制的研究[D]. 贵州: 贵州大学, 2020.
[10] ENSERINK J M, KOLODNER R D. An overview of Cdk1-controlled targets and processes[J]. Cell Div, 2010, 5: 11. DOI: 10.1186/1747-1028-5-11.
[11] BISHOP A, LANE R, BENISTON R, et al. Hyphal growth in Candida albicans requires the phosphorylation of Sec2 by the Cdc28-Ccn1/Hgc1 kinase[J]. Embo J, 2010, 29(17): 2930-2942.
[12] TAVANTI A, HENSGENS L A, MOGAVERO S, et al. Genotypic and phenotypic properties of Candida parapsilosis sensu strictu strains isolated from different geographic regions and body sites[J]. BMC Microbiol, 2010, 10: 203. DOI: 10.1186/1471-2180-10-203.
[13] DE PAULA M R, DE OLIVEIRA MELO S G, BESSA M A S, et al. Candidemia by Candida parapsilosis in a neonatal intensive care unit: human and environmental reservoirs, virulence factors, and antifungal susceptibility[J]. Braz J Microbiol, 2020, 51(3): 851-860.
[14] 张丽, 于淑颖, 宋雅婷, 等. 全国多中心血流分离近平滑念珠菌药物敏感性和分子流行病学回顾性研究[J]. 中国真菌学杂志, 2021, 16(5): 289-295.
[15] LIN D, WU L C, RINALDI M G, et al. Three distinct genotypes within Candida parapsilosis from clinical sources[J]. J Clin Microbiol, 1995, 33(7): 1815-1821.
[16] PFALLER M A, DIEKEMA D J, TURNIDGE J D, et al. Twenty years of the sentry antifungal surveillance program: results for Candida species from 1997-2016[J]. Open Forum Infect Dis, 2019, 6(Suppl 1): S79-S94.
[17] SOUZA A C R, FUCHS B B, ALVES V S, et al. Pathogenesis of the Candida parapsilosis complex in the model host caenorhabditis elegans[J]. Genes (Basel), 2018, 9(8): 401-411.
[18] 张丽. 中国临床多中心近平滑念珠菌流行病学、耐药性及唑类药物耐药机制研究[D]. 北京:北京协和医学院, 2015.
[19] DE FRANCESCO M A, PICCINELLI G, GELMI M, et al. Invasive candidiasis in Brescia, Italy: analysis of species distribution and antifungal susceptibilities during seven years[J]. Mycopathologia, 2017, 182(9-10): 897-905.
[20] SONG Y, CHEN X, YAN Y, et al. Prevalence and antifungal susceptibility of pathogenic yeasts in China: A 10-Year retrospective study in a teaching hospital[J]. Front Microbiol, 2020, 11: 1401. DOI: 10.3389/fmicb.2020.01401.
[21] TASNEEM U, SIDDIQUI M T, FARYAL R, et al. Prevalence and antifungal susceptibility of Candida species in a tertiary care hospital in Islamabad, Pakistan[J]. J Pak Med Assoc, 2017, 67(7): 986-991.
[22] CASTANHEIRA M, DESHPANDE L M, MESSER S A, et al. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination[J]. Int J Antimicrob Agents, 2020, 55(1): 105799. DOI: 10.1016/j.ijantimicag.2019.09.003.
[23] ZHANG L, YU S Y, CHEN S C, et al. Molecular characterization of Candida parapsilosis by microsatellite typing and emergence of clonal antifungal drug resistant strains in a multicenter surveillance in China[J]. Front Microbiol, 2020, 11: 1320. DOI: 10.3389/fmicb.2020.01320.
[24] MARIA S, BARNWAL G, KUMAR A, et al. Species distribution and antifungal susceptibility among clinical isolates of Candida parapsilosis complex from India[J]. Rev Iberoam Micol, 2018, 35(3): 147-150.
[25] ARASTEHFAR A, DANESHNIA F, NAJSFZADEH M J, et al. Evaluation of molecular epidemiology, clinical characteristics, antifungal susceptibility profiles, and molecular mechanisms of antifungal resistance of Iranian Candida parapsilosis species complex blood isolates[J]. Front Cell Infect Microbiol, 2020, 10: 206. DOI: 10.3389/fcimb.2020.00206.
[26] MARTINI C, TORELLI R, DE G T, et al. Prevalence and clonal distribution of azole-resistant Candida parapsilosis isolates causing bloodstream infections in a large Italian hospital[J]. Front Cell Infect Microbiol, 2020, 10: 232. DOI: 10.3389/fcimb.2020.00232.
[27] WU Y, WEI D, GONG X, et al. Initial use of voriconazole positively affects outcome of Candida parapsilosis bloodstream infection: a retrospective analysis[J]. Transl Pediatr, 2020, 9(4): 480-486.
[28] RAMAGE G, MARTINEZ J P, LOPEZ-RIBOT J L. Candida biofilms on implanted biomaterials: a clinically significant problem[J]. FEMS Yeast Res, 2006, 6(7): 979-986.
[29] VITALIS E, NAGY F, TOYH Z, et al. Candida biofilm production is associated with higher mortality in patients with candidaemia[J]. Mycoses, 2020, 63(4): 352-360.
[30] DIAS L P, SOUZA P F N, OLIVEIRA J T A, et al. RcAlb-PepII, a synthetic small peptide bioinspired in the 2S albumin from the seed cake of ricinus communis, is a potent antimicrobial agent against klebsiella pneumoniae and Candida parapsilosis[J]. Biochim Biophys Acta Biomembr, 2020, 1862(2): 183092. DOI:10.1016/j.bbamem.2019.183092.
[31] FAIS R, DI M, RIZZATO C, et al. The N-terminus of human lactoferrin displays anti-biofilm activity on Candida parapsilosis in lumen catheters[J]. Front Microbiol, 2017, 8: 2218. DOI: 10.3389/fmicb.2017.02218.
[32] 成荣, 李红凌, 胡方芳, 等. 抗真菌肽MAF-1A体外对近平滑念珠菌生物膜形成能力的影响,与生物膜结合及抑菌情况观察[J]. 山东医药, 2020, 60(18): 30-34.
[33] SENN H, SHAPIRO R S, COWEN L E. Cdc28 provides a molecular link between Hsp90, morphogenesis, and cell cycle progression in Candida albicans[J]. Mol Biol Cell, 2012, 23(2): 268-283.
[34] GREIG J A, SUDBERY I M, RICHARDSON J P, et al. Cell cycle-independent phospho-regulation of Fkh2 during hyphal growth regulates Candida albicans pathogenesis[J]. PLoS Pathog, 2015, 11(1): e1004630. DOI:10.1371/journal.ppat.1004630